Developer docs
API playgroundTry for free, no card

Search company profiles

Biodol Therapeutics

Full company profile

uuid0002veo

Namestring
Biodol Therapeutics
Legal namestring
Biodol Therapeutics
Websiteurl
biodol.eu
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Biodol Therapeutics is a France-based clinical-stage biopharmaceutical company, founded in 2015 and headquartered in Montarnaud near Montpellier, developing first-in-class small-molecule FLT3 inhibitors for the treatment of chronic neuropathic pain and opioid-sparing indications. The company's core scientific thesis — validated in Nature Communications in 2018 and extended in 2024 — is that the Receptor Tyrosine Kinase FLT3 is a necessary and sufficient driver of chronic neuropathic pain, and that extracellular Negative Allosteric Modulators of FLT3 can reverse established pain (allodynia, hyperalgesia, spontaneous pain) for 48 hours after a single dose in animal models while sparing normal nervous system function. Biodol's lead asset, BDT272, entered Phase 1 clinical trials in healthy volunteers in 2025, with the broader BDT series (including BDT001) and additional oral-formulation candidates in lead optimization.

The company monetizes exclusively through pharmaceutical licensing rather than direct commercialization. Its portfolio is anchored by four granted patents, including an international composition-of-matter patent and a use patent covering any FLT3 inhibitor to treat neuropathic pain, with protection granted in both the United States and Europe. Biodol's go-to-market relies on industry partnering events (BIO, BIO-Europe, J.P. Morgan Week), academic collaborations with INSERM Montpellier and CNRS Strasbourg, and strategic licensing agreements — most notably the March 2026 license agreement with KYORIN Pharmaceutical for BDT272. Cumulative funding is approximately €11.5 million (€4.5M Series A from V-Bio Ventures in August 2020; €7M in May 2024 with Bpifrance and V-Bio Ventures), and the company employs 11-50 people.

Short descriptiontext

Biodol Therapeutics is a France-based clinical-stage biotech developing first-in-class small-molecule FLT3 inhibitors for chronic neuropathic pain and opioid dose-sparing applications. It monetizes through pharmaceutical licensing, with BDT272 in Phase 1 trials and a KYORIN license signed in March 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontarnaud, France
HQ citystring
Montarnaud
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuropathic pain therapeutics, FLT3 inhibitors, small molecule drug discovery, chronic pain treatment, biopharmaceutical pipeline
Industry4 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pain Therapeutics / Biopharmaceutical R&D
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Royalties
TypeLicensing Royalties
Description

Future revenue through licensing agreements with pharmaceutical companies for their BDT compounds and patent portfolio. License agreement signed with KYORIN Pharmaceutical in March 2026.

biodol.eu
2Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from commercializing first-in-class neuropathic pain treatments (BDT272 and pipeline compounds) developed for injectable or oral administration.

biodol.eu
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biodol Therapeutics discovers and develops first-in-class small-molecule FLT3 inhibitors (BDT compounds) as Negative Allosteric Modulators for the treatment of chronic neuropathic pain and for opioid-dose sparing applications. The lead candidate BDT272 is in Phase 1 clinical trials in healthy volunteers (reported May 2025), with formulations pursued as both injectable and oral therapies. The company monetizes this pipeline through licensing agreements with pharmaceutical partners (e.g., KYORIN Pharmaceutical, March 2026) rather than direct commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Single administration completely reverses established neuropathic pain symptoms including hyperalgesia, allodynia and spontaneous signs of pain
+3 more records
Product overview1 text field

Biodol Therapeutics is a biopharmaceutical company developing a portfolio of first-in-class small-molecule FLT3 inhibitors (BDT compounds) for the treatment of chronic neuropathic pain. The core product pipeline includes BDT272 (currently in Phase 1 clinical trials), the BDT series of Negative Allosteric Modulators targeting the extracellular domain of FLT3, and BDT001 (the first discovered extracellular inhibitor). The company is developing these compounds as both injectable and oral formulations, with potential for opioid-dose sparing applications to address the Opioid Crisis. BDT compounds have demonstrated remarkable activity against neuropathic pain in animal models, with effects lasting 48 hours.

Product and service3 records
1BDT272
CategoryCore pipeline asset (preclinical/Phase 1 small molecule)
Description

BDT272 is Biodol's first-in-class FLT3 inhibitor in Phase 1 clinical trials, being developed for chronic neuropathic pain as both injectable and oral therapy.

2BDT compound series (extracellular FLT3 Negative Allosteric Modulators)
CategoryCore pipeline asset (small molecule platform)
Description

The BDT compound series are first-in-class small-molecule FLT3 inhibitors acting at the extracellular domain of FLT3 as Negative Allosteric Modulators, targeting chronic neuropathic pain and offering opioid-dose sparing applications.

3BDT001
CategoryLead discovery compound (small molecule)
Description

BDT001 is the original extracellular inhibitor of FLT3 identified through virtual screening, demonstrated to reverse neuropathic pain symptoms in animal models and protected by patent.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-31
Description

License agreement signed for novel neuropathic pain treatment. KYORIN Pharmaceutical obtained rights to develop and commercialize BDT272 for neuropathic pain treatment. Prior option agreement was announced in January 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with Cyril Rivat and Jean Valmier for discovery of FLT3 role in chronic pain. Jean Valmier serves as Principal Scientific Advisor and leads the laboratory at INSERM Institute for Neurosciences of Montpellier (INM).

3Laboratory for Therapeutic Innovation (LIT) - CNRS/Université de Strasbourg
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership with Didier Rognan as Research Director at CNRS and Director of LIT. Didier Rognan is a worldwide recognized specialist of virtual screening and contributed to development of BDT compounds through virtual screening.

biodol.eu
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a first-in-class selective NaV1.8 inhibitor for acute pain in 2025, with ongoing development in neuropathic pain. As a developer of first-in-class small-molecule pain therapeutics with strong clinical and commercial capabilities, Vertex is the most directly comparable peer to Biodol's BDT272 program.

TypeBroad incumbent
Description

Grünenthal is a German privately-held pharmaceutical company specializing in pain therapeutics, with a portfolio including established products in neuropathic pain (e.g., Versatis/lidocaine patch, Qutenza/capsaicin) and active development of novel pain mechanisms. Comparable as a focused pain franchise player where Biodol's pipeline could fit as a licensing partner or acquirer.

3Eliem Therapeutics
TypeEmerging player
Description

Eliem Therapeutics is a clinical-stage biotechnology company developing novel treatments for hyperexcitability disorders of the central nervous system, including neuropathic pain. Comparable as an emerging biotech with similar size, clinical-stage CNS/pain pipeline, and licensing-oriented business model to Biodol.

TypeEmerging player
Description

Latigo Biotherapeutics is a clinical-stage biotech developing non-opioid pain therapeutics targeting Nav1.7 and Nav1.8 sodium channels. Comparable as an emerging pain-focused biotech pursuing novel small-molecule mechanisms in neuropathic pain, with similar clinical-stage development profile to Biodol's BDT272.

TypeEmerging player
Description

Hoba Therapeutics is a Danish biotech developing novel therapeutics for chronic neuropathic pain, including biologics targeting specific pain pathways. Comparable as a small emerging European biotech focused exclusively on neuropathic pain indications with novel mechanism approaches.

TypeBroad incumbent
Description

Lexicon Pharmaceuticals has historically developed pain therapeutics including those targeting novel mechanisms in neuropathic pain. Comparable as a mid-cap biopharmaceutical company with clinical-stage pain pipeline assets and partnership-oriented business model.

TypeBroad incumbent
Description

AbbVie markets major neuropathic pain treatments (e.g., Botox for chronic migraine, established CNS franchise) and is a frequent partner/licensee for mid-stage pain biotechs. Comparable as a large incumbent with established commercial channels in neuropathic pain that Biodol could partner with for ex-Japan rights.

TypeBroad incumbent
Description

Pfizer markets Lyrica (pregabalin), one of the leading approved treatments for neuropathic pain, and has active interest in novel pain mechanisms. Comparable as a broad incumbent with major neuropathic pain franchise and a logical potential licensor for Biodol's BDT272 outside Asia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biodol Therapeutics

Pain Therapeutics / Biopharmaceutical R&Dbiodol.eu

Biodol Therapeutics is a France-based clinical-stage biotech developing first-in-class small-molecule FLT3 inhibitors for chronic neuropathic pain and opioid dose-sparing applications. It monetizes through pharmaceutical licensing, with BDT272 in Phase 1 trials and a KYORIN license signed in March 2026.

What Biodol Therapeutics does

Biodol Therapeutics is a France-based clinical-stage biopharmaceutical company, founded in 2015 and headquartered in Montarnaud near Montpellier, developing first-in-class small-molecule FLT3 inhibitors for the treatment of chronic neuropathic pain and opioid-sparing indications. The company's core scientific thesis — validated in Nature Communications in 2018 and extended in 2024 — is that the Receptor Tyrosine Kinase FLT3 is a necessary and sufficient driver of chronic neuropathic pain, and that extracellular Negative Allosteric Modulators of FLT3 can reverse established pain (allodynia, hyperalgesia, spontaneous pain) for 48 hours after a single dose in animal models while sparing normal nervous system function. Biodol's lead asset, BDT272, entered Phase 1 clinical trials in healthy volunteers in 2025, with the broader BDT series (including BDT001) and additional oral-formulation candidates in lead optimization.

The company monetizes exclusively through pharmaceutical licensing rather than direct commercialization. Its portfolio is anchored by four granted patents, including an international composition-of-matter patent and a use patent covering any FLT3 inhibitor to treat neuropathic pain, with protection granted in both the United States and Europe. Biodol's go-to-market relies on industry partnering events (BIO, BIO-Europe, J.P. Morgan Week), academic collaborations with INSERM Montpellier and CNRS Strasbourg, and strategic licensing agreements — most notably the March 2026 license agreement with KYORIN Pharmaceutical for BDT272. Cumulative funding is approximately €11.5 million (€4.5M Series A from V-Bio Ventures in August 2020; €7M in May 2024 with Bpifrance and V-Bio Ventures), and the company employs 11-50 people.

Biodol Therapeutics firmographics

Firmographics
Name
Biodol Therapeutics
Legal name
Biodol Therapeutics
Website
https://biodol.eu
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Biodol Therapeutics is a France-based clinical-stage biotech developing first-in-class small-molecule FLT3 inhibitors for chronic neuropathic pain and opioid dose-sparing applications. It monetizes through pharmaceutical licensing, with BDT272 in Phase 1 trials and a KYORIN license signed in March 2026.
Ownership category
akta.pro rank

Biodol Therapeutics industry classification

Industry
Product category
Pain Therapeutics / Biopharmaceutical R&D
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Neuropathic pain therapeutics
  • FLT3 inhibitors
  • Small molecule drug discovery
  • Chronic pain treatment
  • Biopharmaceutical pipeline

Where Biodol Therapeutics is headquartered

Location

Headquarters

HQ city
Montarnaud
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Biodol Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Royalties: Future revenue through licensing agreements with pharmaceutical companies for their BDT compounds and patent portfolio. License agreement signed with KYORIN Pharmaceutical in March 2026.
  2. Pharmaceutical Product Sales: Revenue from commercializing first-in-class neuropathic pain treatments (BDT272 and pipeline compounds) developed for injectable or oral administration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Biodol Therapeutics product offering

Product offering

Core offering

Biodol Therapeutics discovers and develops first-in-class small-molecule FLT3 inhibitors (BDT compounds) as Negative Allosteric Modulators for the treatment of chronic neuropathic pain and for opioid-dose sparing applications. The lead candidate BDT272 is in Phase 1 clinical trials in healthy volunteers (reported May 2025), with formulations pursued as both injectable and oral therapies. The company monetizes this pipeline through licensing agreements with pharmaceutical partners (e.g., KYORIN Pharmaceutical, March 2026) rather than direct commercialization.

Product overview

Biodol Therapeutics is a biopharmaceutical company developing a portfolio of first-in-class small-molecule FLT3 inhibitors (BDT compounds) for the treatment of chronic neuropathic pain. The core product pipeline includes BDT272 (currently in Phase 1 clinical trials), the BDT series of Negative Allosteric Modulators targeting the extracellular domain of FLT3, and BDT001 (the first discovered extracellular inhibitor). The company is developing these compounds as both injectable and oral formulations, with potential for opioid-dose sparing applications to address the Opioid Crisis. BDT compounds have demonstrated remarkable activity against neuropathic pain in animal models, with effects lasting 48 hours.

Differentiator

Problem solved

Functional benefit

Products and services

  • BDT272 BDT272 is Biodol's first-in-class FLT3 inhibitor in Phase 1 clinical trials, being developed for chronic neuropathic pain as both injectable and oral therapy.
  • BDT compound series (extracellular FLT3 Negative Allosteric Modulators) The BDT compound series are first-in-class small-molecule FLT3 inhibitors acting at the extracellular domain of FLT3 as Negative Allosteric Modulators, targeting chronic neuropathic pain and offering opioid-dose sparing applications.
  • BDT001 BDT001 is the original extracellular inhibitor of FLT3 identified through virtual screening, demonstrated to reverse neuropathic pain symptoms in animal models and protected by patent.

Quantifiable outcome

  • Single administration completely reverses established neuropathic pain symptoms including hyperalgesia, allodynia and spontaneous signs of pain
  • +3 more outcomes

Companies that use Biodol Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Biodol Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Biodol Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • KYORIN PharmaceuticalflagshipOEM/ Whitelabel/ Licensing Partner · 31 March 2026License agreement signed for novel neuropathic pain treatment. KYORIN Pharmaceutical obtained rights to develop and commercialize BDT272 for neuropathic pain treatment. Prior option agreement was announced in January 2025.
  • INSERM Institute for Neurosciences of MontpelliercoreStrategic or Co-development PartnerAcademic partnership with Cyril Rivat and Jean Valmier for discovery of FLT3 role in chronic pain. Jean Valmier serves as Principal Scientific Advisor and leads the laboratory at INSERM Institute for Neurosciences of Montpellier (INM).
  • Laboratory for Therapeutic Innovation (LIT) - CNRS/Université de StrasbourgcoreStrategic or Co-development PartnerAcademic research partnership with Didier Rognan as Research Director at CNRS and Director of LIT. Didier Rognan is a worldwide recognized specialist of virtual screening and contributed to development of BDT compounds through virtual screening.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Biodol Therapeutics competitors and assessment

Company assessment

Direct peers

  • Vertex Pharmaceuticals: Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a first-in-class selective NaV1.8 inhibitor for acute pain in 2025, with ongoing development in neuropathic pain. As a developer of first-in-class small-molecule pain therapeutics with strong clinical and commercial capabilities, Vertex is the most directly comparable peer to Biodol's BDT272 program.

Broad incumbents

  • Grünenthal: Grünenthal is a German privately-held pharmaceutical company specializing in pain therapeutics, with a portfolio including established products in neuropathic pain (e.g., Versatis/lidocaine patch, Qutenza/capsaicin) and active development of novel pain mechanisms. Comparable as a focused pain franchise player where Biodol's pipeline could fit as a licensing partner or acquirer.
  • Lexicon Pharmaceuticals: Lexicon Pharmaceuticals has historically developed pain therapeutics including those targeting novel mechanisms in neuropathic pain. Comparable as a mid-cap biopharmaceutical company with clinical-stage pain pipeline assets and partnership-oriented business model.
  • AbbVie: AbbVie markets major neuropathic pain treatments (e.g., Botox for chronic migraine, established CNS franchise) and is a frequent partner/licensee for mid-stage pain biotechs. Comparable as a large incumbent with established commercial channels in neuropathic pain that Biodol could partner with for ex-Japan rights.
  • Pfizer: Pfizer markets Lyrica (pregabalin), one of the leading approved treatments for neuropathic pain, and has active interest in novel pain mechanisms. Comparable as a broad incumbent with major neuropathic pain franchise and a logical potential licensor for Biodol's BDT272 outside Asia.

Emerging players

  • Eliem Therapeutics: Eliem Therapeutics is a clinical-stage biotechnology company developing novel treatments for hyperexcitability disorders of the central nervous system, including neuropathic pain. Comparable as an emerging biotech with similar size, clinical-stage CNS/pain pipeline, and licensing-oriented business model to Biodol.
  • Latigo Biotherapeutics: Latigo Biotherapeutics is a clinical-stage biotech developing non-opioid pain therapeutics targeting Nav1.7 and Nav1.8 sodium channels. Comparable as an emerging pain-focused biotech pursuing novel small-molecule mechanisms in neuropathic pain, with similar clinical-stage development profile to Biodol's BDT272.
  • Hoba Therapeutics: Hoba Therapeutics is a Danish biotech developing novel therapeutics for chronic neuropathic pain, including biologics targeting specific pain pathways. Comparable as a small emerging European biotech focused exclusively on neuropathic pain indications with novel mechanism approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Biodol Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biodol Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Biodol Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biodol Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biodol Therapeutics

What does Biodol Therapeutics do?

Biodol Therapeutics discovers and develops first-in-class small-molecule FLT3 inhibitors (BDT compounds) as Negative Allosteric Modulators for the treatment of chronic neuropathic pain and for opioid-dose sparing applications. The lead candidate BDT272 is in Phase 1 clinical trials in healthy volunteers (reported May 2025), with formulations pursued as both injectable and oral therapies. The company monetizes this pipeline through licensing agreements with pharmaceutical partners (e.g., KYORIN Pharmaceutical, March 2026) rather than direct commercialization.

Is Biodol Therapeutics a public or private company?

Biodol Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biodol Therapeutics founded?

Biodol Therapeutics was founded in 2015. It employs 1 to 10 people.

Where is Biodol Therapeutics based?

Biodol Therapeutics is headquartered in Montarnaud, France, in the Europe region.

How does Biodol Therapeutics make money?

Two revenue lines are on record. Licensing Royalties are the primary driver. The others are pharmaceutical Product Sales.

Who are Biodol Therapeutics's main competitors?

Vertex Pharmaceuticals is listed as a direct peer. Broad incumbents are Grünenthal, Lexicon Pharmaceuticals, AbbVie and Pfizer. Emerging players are Eliem Therapeutics, Latigo Biotherapeutics and Hoba Therapeutics.

Does Biodol Therapeutics have an API?

No public API is recorded for Biodol Therapeutics.

What industry is Biodol Therapeutics in?

Biodol Therapeutics's product category is Pain Therapeutics / Biopharmaceutical R&D. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals